Follow the 메타바이오메드 share price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares trade on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 메타바이오메드 has published 37 public disclosures. Market capitalisation: €104.7bn. The latest transaction was filed on 25 August 2026 (Purchase). Among the most active insiders: 오지수. All data is accessible without an account.
37
Insider Decl.
n/a
Thresholds
€1,687
28 ops.
Buy Volume
n/a
1 ops.
Sell Volume
15Σ signal
Buys €1,687n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 6,445 of 29,063 companies
65.5
score / 100
Value
68
Quality
64
FCF yld-0.6%
Earn yld10%
EV/EBITDA7.1x
ROE·
Gross mgn52%
Net mgn11%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Meta Biomed es una empresa que cotiza en el mercado XKRX, especializada en el sector de la salud y farmacéutico. Se centra en el desarrollo y la comercialización de soluciones innovadoras para el campo médico.